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Rationale
In patients with symptomatic asthma receiving ICS or ICS
+LABA, Phase III studies have demonstrated improved
lung function with tiotropium Respimat®, a once-daily
long-acting anticholinergic bronchodilator. The efficacy of
some treatments (eg ICS and omalizumab), appears higher
in TH2-high phenotypes, but no specific treatments are
available that work equally well in both TH2-high and
TH2-low phenotypes. We explored whether TH2 biomar-
ker status influenced responses to tiotropium in patients
with moderate symptomatic asthma.
Methods
In two replicate Phase III, randomized, double-blind, pla-
cebo-controlled, parallel-group trials (NCT01172808/
NCT01172821), patients with moderate symptomatic
asthma, using medium-dose ICS (400-800 µg budesonide
equivalent), were administered once-daily tiotropium
Respimat® 5 µg or 2.5 µg, placebo, or salmeterol (active
comparator without inferential analysis). Co-primary
endpoints included peak and trough FEV1 response (dif-
ference from baseline) at 24 weeks. Pre-planned analyses
(pooled population) were performed in TH2-high and
TH2-low subgroups defined at baseline as total serum IgE
≤ or >430 µg/L) or blood eosinophils ≤ or >0.6×109/L.
Results
Of 1545 patients in the full analysis set who received tio-
tropium or placebo, 915/1455 were reported with IgE
>430 µg/L and 300/1461 with an eosinophil count of
>0.6×109/L. Peak FEV1 improved with tiotropium versus
placebo, independent of IgE (p<0.0001 both doses) and
eosinophil count (p<0.0001 both doses). Trough FEV1 also
improved with tiotropium versus placebo, irrespective of
IgE (p<0.0001 both doses) and eosinophil count (p<0.005
both doses).
Conclusions
Once-daily tiotropium Respimat® as add-on to ICS
reduces airflow obstruction in patients with moderate
symptomatic asthma, independent of TH2 phenotype,
and thus may potentially provide an important thera-
peutic option.
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